Global biopharmaceutical company CSL announced a significant expansion of its United States operations, committing approximately US$1.5 billion in new capital investments over the next five years to increase the nation’s manufacturing capacity for plasma-derived therapies. The initiative reflects the company’s long-term strategy to meet rising clinical demand for immunoglobulin treatments and further reinforce the reliability of the U.S. medicine supply chain.
The planned investment builds on more than US$3 billion CSL has invested across its U.S. operations since 2018, an effort that has created over 6,500 jobs nationwide and brought its American workforce to nearly 19,000. Representing about 65 percent of its global headcount, the United States remains CSL’s most significant employment base and a core driver of its manufacturing and scientific capabilities.
The company said its latest commitment will support the creation of hundreds of additional high-quality jobs ranging from scientific roles to advanced manufacturing positions. It will also expand onshore production of plasma-derived therapies, which remain vital treatments for patients with rare and serious diseases. CSL added that the new investment continues its mission to support patient care, strengthen U.S. therapeutic self-sufficiency, and create new opportunities for American workers entering the healthcare and biotechnology sectors.
CSL noted that these investments remain subject to approval by its Board of Directors.
The company also emphasized the role its national plasma collection network plays in expanding healthcare career pathways. CSL’s plasma centers provide entry-level opportunities that often lead to long-term advancement in clinical and research fields, supporting thousands of employees across numerous states.
CSL operates globally across three major businesses: CSL Behring, CSL Seqirus and CSL Vifor. With a portfolio spanning treatments for haemophilia, immune deficiencies, influenza prevention and conditions related to iron deficiency, dialysis and nephrology, CSL supplies lifesaving products to patients in more than 100 countries. Founded in 1916, the company employs more than 29,000 people worldwide and continues to focus on research, development and manufacturing excellence to deliver innovative therapies.
KEY QUOTE:
“The U.S. is the world’s leading source for plasma, the main component of plasma derived therapies. These important medicines are often the most effective or only therapies available for many rare or serious diseases. By expanding our onshore production capacity in the U.S., we are deepening our commitment to patient care, creating high-quality jobs and driving innovation in the U.S.”
Paul McKenzie, Chief Executive Officer and Managing Director, CSL
